OTCMKTS:ASPHF Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis → The key to this new pathway to wealth is literally a key (From Porter & Company) (Ad) Free ASPHF Stock Alerts $2.69 0.00 (0.00%) (As of 06/28/2024 ET) Add Compare Share Share Today's Range$2.69▼$2.6950-Day Range$2.50▼$2.6952-Week Range$2.35▼$3.63Volume31,600 shsAverage Volume950 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Ascentage Pharma Group International alerts: Email Address Ad The Freeport SocietyOdds of Biden Replacement Up 105%!The media has now officially turned on him. But while Trump supporters are celebrating… The Democratic party is readying a Plan B that could change the face of America forever.Click here for my urgent election update. About Ascentage Pharma Group International Stock (OTCMKTS:ASPHF)Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation. It also has APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449, an oral bioavailable inhibitor of FAK, ROS1, and ALK tyrosine kinases; APG-5918, an orally available and selective EED inhibitor; APG-265, a MDM2 protein degrade; and UBX1967/1325. In, addition it engages in medical research and development; venture capital investment; and rental services. The company has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.Read More ASPHF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASPHF Stock News HeadlinesJune 23, 2024 | prnewswire.comAscentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary SharesJune 18, 2024 | prnewswire.comLive from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORRJune 29, 2024 | Paradigm Press (Ad)Elon Musk: “This Could be Massive…a Multi Trillion-Dollar Company.”Have you seen Elon Musk’s latest crazy prediction?June 14, 2024 | prnewswire.comAscentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)June 4, 2024 | prnewswire.comLive from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WMJune 1, 2024 | prnewswire.comLive from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLCMay 23, 2024 | prnewswire.comASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug CandidatesMay 15, 2024 | prnewswire.comEHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid CongressJune 29, 2024 | Paradigm Press (Ad)Elon Musk: “This Could be Massive…a Multi Trillion-Dollar Company.”Have you seen Elon Musk’s latest crazy prediction?April 24, 2024 | prnewswire.comASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GISTApril 7, 2024 | prnewswire.comAACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual MeetingSee More Headlines Receive ASPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:ASPHF CUSIPN/A CIKN/A Webwww.ascentagepharma.com Phone86-512-8555-7777FaxN/AEmployees565Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Dajun Yang M.D. (Age 61)Ph.D., Co-Founder, Chairman & CEO Comp: $556.95kDr. Shaomeng Wang Ph.D. (Age 59)Co-Founder, Chief Scientific Advisor & Non-Executive Director Comp: $154.02kDr. Ming Guo (Age 66)Co-Founder Mr. Thomas Knapp (Age 72)Senior VP & General Counsel Dr. Yifan Zhai M.D. (Age 61)Ph.D., Chief Medical Officer Douglas Dong FangSenior Vice President of Preclinical DevelopmentJianfeng WenSenior Vice President of Pharmaceutical ScienceMr. Raymond Kmetz (Age 66)Chief Business Officer Mr. Yifei Zhu (Age 54)Chief Commercial Officer Mr. Cheung Ki Wong A.C.I.S. (Age 41)A.C.S., FCPA, Company Secretary More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors ASPHF Stock Analysis - Frequently Asked Questions How have ASPHF shares performed in 2024? Ascentage Pharma Group International's stock was trading at $3.21 at the beginning of the year. Since then, ASPHF stock has decreased by 16.2% and is now trading at $2.69. View the best growth stocks for 2024 here. Are investors shorting Ascentage Pharma Group International? Ascentage Pharma Group International saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 420,800 shares, a drop of 6.8% from the May 15th total of 451,400 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days. View Ascentage Pharma Group International's Short Interest. How do I buy shares of Ascentage Pharma Group International? Shares of ASPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ASPHF) was last updated on 6/29/2024 by MarketBeat.com Staff From Our PartnersJoe Biden Facing Political “Knockout” In Weeks?Joe Biden Facing Political “Knockout” In Weeks? Weeks from now, we are expecting Joe Biden to make a histor...Banyan Hill Publishing | SponsoredBiden’s inner circle turns against him?On August 19, the Democratic party will take the stage in Chicago and officially nominate their presidential c...Paradigm Press | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredNext-Gen AI is Creating Millionaires Right NowI predict massive unemployment is coming. 800 million could lose their jobs, according to a McKinsey study,...InvestorPlace | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.